PL3246016T3 - Kompozycja suchego proszku zawierająca inhibitor fosfodiesterazy - Google Patents

Kompozycja suchego proszku zawierająca inhibitor fosfodiesterazy

Info

Publication number
PL3246016T3
PL3246016T3 PL17176635.5T PL17176635T PL3246016T3 PL 3246016 T3 PL3246016 T3 PL 3246016T3 PL 17176635 T PL17176635 T PL 17176635T PL 3246016 T3 PL3246016 T3 PL 3246016T3
Authority
PL
Poland
Prior art keywords
composition containing
dry powder
powder composition
phosphodiesterase inhibitor
containing phosphodiesterase
Prior art date
Application number
PL17176635.5T
Other languages
English (en)
Inventor
Daniela Cocconi
Francesca Schiaretti
Roberto Bilzi
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of PL3246016T3 publication Critical patent/PL3246016T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17176635.5T 2010-08-03 2011-07-27 Kompozycja suchego proszku zawierająca inhibitor fosfodiesterazy PL3246016T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10171748 2010-08-03

Publications (1)

Publication Number Publication Date
PL3246016T3 true PL3246016T3 (pl) 2025-06-16

Family

ID=43262631

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11741172T PL2600830T3 (pl) 2010-08-03 2011-07-27 Kompozycja suchego proszku zawierająca inhibitor fosfodiesterazy
PL17176635.5T PL3246016T3 (pl) 2010-08-03 2011-07-27 Kompozycja suchego proszku zawierająca inhibitor fosfodiesterazy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11741172T PL2600830T3 (pl) 2010-08-03 2011-07-27 Kompozycja suchego proszku zawierająca inhibitor fosfodiesterazy

Country Status (39)

Country Link
US (2) US9132121B2 (pl)
EP (2) EP2600830B1 (pl)
JP (1) JP6004233B2 (pl)
KR (1) KR101805958B1 (pl)
CN (2) CN103052379A (pl)
AR (1) AR082443A1 (pl)
AU (1) AU2011287711B2 (pl)
BR (1) BR112013002506A2 (pl)
CA (1) CA2807256C (pl)
CL (1) CL2013000293A1 (pl)
CO (1) CO6690744A2 (pl)
CY (1) CY1120605T1 (pl)
DK (2) DK2600830T3 (pl)
EA (2) EA027692B1 (pl)
ES (2) ES2664175T3 (pl)
FI (1) FI3246016T3 (pl)
GE (1) GEP20156343B (pl)
HR (2) HRP20180717T1 (pl)
HU (2) HUE037620T2 (pl)
IL (1) IL224517B (pl)
LT (2) LT2600830T (pl)
MA (1) MA34449B1 (pl)
ME (1) ME03022B (pl)
MX (1) MX346424B (pl)
MY (1) MY179703A (pl)
NO (1) NO2600830T3 (pl)
NZ (1) NZ606548A (pl)
PE (2) PE20130601A1 (pl)
PH (1) PH12013500235A1 (pl)
PL (2) PL2600830T3 (pl)
PT (2) PT2600830T (pl)
RS (2) RS57061B1 (pl)
SG (1) SG187258A1 (pl)
SI (2) SI3246016T1 (pl)
SM (1) SMT202500256T1 (pl)
TR (1) TR201807012T4 (pl)
UA (1) UA112296C2 (pl)
WO (1) WO2012016889A2 (pl)
ZA (1) ZA201300870B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
EP3143987A1 (en) 2010-08-03 2017-03-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
MX2013013557A (es) 2011-06-06 2013-12-16 Chiesi Farma Spa Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa.
WO2014072937A1 (en) 2012-11-08 2014-05-15 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
ES2744542T3 (es) * 2013-03-15 2020-02-25 Robert I Henkin Inhibidores de fosfodiesterasa para tratar trastornos gustativos y olfativos
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
FI3587400T3 (fi) * 2013-10-22 2024-06-20 Chiesi Farm Spa Menetelmä pde4:n estäjän valmistamiseksi
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
CN104800192A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入粉雾剂及制备方法
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
ES2701525T3 (es) 2014-07-09 2019-02-22 Arven Ilac Sanayi Ve Ticaret As Un procedimiento para la preparación de formulaciones para inhalación
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
WO2021194893A1 (en) 2020-03-24 2021-09-30 Cyrano Therapeutics, Inc. Treatment of chemosensory dysfunction from a coronavirus infection
US20250058063A1 (en) 2021-12-21 2025-02-20 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
KR20250006225A (ko) 2022-04-27 2025-01-10 키에시 파르마슈티시 엣스. 피. 에이. Pde4 억제제의 결정형
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
WO2024062007A1 (en) * 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
CN119923251A (zh) * 2022-09-22 2025-05-02 奇斯药制品公司 用于施用磷酸二酯酶-4抑制剂的胶囊吸入器
EP4590273A1 (en) * 2022-09-22 2025-07-30 Chiesi Farmaceutici S.p.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19841248A1 (de) 1997-09-12 1999-04-29 Fraunhofer Ges Forschung Demonstrationseinrichtung in Form eines Lebewesens
DE59801018D1 (de) 1997-09-16 2001-08-16 Trench Switzerland Ag Basel Spannungsteiler
PL196951B1 (pl) 1999-03-05 2008-02-29 Chiesi Farma Spa Proszek do stosowania w inhalatorze suchego proszku, cząsteczki nośnika i sposób wytwarzania nośnika
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
PT1913939T (pt) 2000-06-27 2017-07-19 Vectura Ltd Formulações para utilização em dispositivos inalatórios
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
DE60239639D1 (de) 2002-07-31 2011-05-12 Chiesi Farma Spa Pulverinhalator
DE10255387A1 (de) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Tiotropium-haltige Pulverformulierung für die Inhalation
GB0326632D0 (en) * 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
BRPI0610877A2 (pt) * 2005-06-06 2010-08-03 Hoffmann La Roche compostos, processo para a manufatura dos compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de l-cpt1 e utilização dos mesmos
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) * 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
EP3143987A1 (en) 2010-08-03 2017-03-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
MX2013013557A (es) 2011-06-06 2013-12-16 Chiesi Farma Spa Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa.
FI3587400T3 (fi) 2013-10-22 2024-06-20 Chiesi Farm Spa Menetelmä pde4:n estäjän valmistamiseksi

Also Published As

Publication number Publication date
NO2600830T3 (pl) 2018-07-21
LT3246016T (lt) 2025-05-26
EP3246016A1 (en) 2017-11-22
CN106890165A (zh) 2017-06-27
PE20130601A1 (es) 2013-05-30
CN103052379A (zh) 2013-04-17
AR082443A1 (es) 2012-12-05
EP2600830B1 (en) 2018-02-21
PT2600830T (pt) 2018-04-02
SMT202500256T1 (it) 2025-09-12
NZ606548A (en) 2015-02-27
HUE037620T2 (hu) 2018-09-28
US9132121B2 (en) 2015-09-15
JP2013532705A (ja) 2013-08-19
ES2664175T3 (es) 2018-04-18
HRP20250711T1 (hr) 2025-08-15
MX2013001172A (es) 2013-03-07
HUE071256T2 (hu) 2025-08-28
EP2600830A2 (en) 2013-06-12
WO2012016889A2 (en) 2012-02-09
MX346424B (es) 2017-03-21
DK2600830T3 (en) 2018-03-12
HRP20180717T1 (hr) 2018-07-13
DK3246016T3 (da) 2025-05-19
EA024922B1 (ru) 2016-11-30
ME03022B (me) 2018-10-20
AU2011287711B2 (en) 2016-10-27
US20120031403A1 (en) 2012-02-09
MA34449B1 (fr) 2013-08-01
KR101805958B1 (ko) 2017-12-07
CL2013000293A1 (es) 2013-05-03
EA201690541A1 (ru) 2016-07-29
MY179703A (en) 2020-11-11
EP3246016B1 (en) 2025-04-09
RS66876B1 (sr) 2025-07-31
US9308200B2 (en) 2016-04-12
CO6690744A2 (es) 2013-06-17
BR112013002506A2 (pt) 2016-05-31
CY1120605T1 (el) 2019-12-11
EA027692B1 (ru) 2017-08-31
PT3246016T (pt) 2025-06-25
UA112296C2 (uk) 2016-08-25
PH12013500235A1 (en) 2016-05-25
ES3033142T3 (en) 2025-07-31
KR20130094784A (ko) 2013-08-26
PL2600830T3 (pl) 2018-08-31
WO2012016889A3 (en) 2012-04-19
IL224517B (en) 2018-04-30
LT2600830T (lt) 2018-04-10
CA2807256A1 (en) 2012-02-09
SG187258A1 (en) 2013-03-28
RS57061B1 (sr) 2018-06-29
PE20171256A1 (es) 2017-08-28
EA201390049A1 (ru) 2013-05-30
ZA201300870B (en) 2014-04-30
FI3246016T3 (fi) 2025-07-08
US20150342936A1 (en) 2015-12-03
SI2600830T1 (en) 2018-05-31
CA2807256C (en) 2018-08-28
SI3246016T1 (sl) 2025-06-30
JP6004233B2 (ja) 2016-10-05
TR201807012T4 (tr) 2018-06-21
GEP20156343B (en) 2015-08-10
AU2011287711A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
HUE071256T2 (hu) Foszfodiészteráz inhibitor tartalmú száraz porkészítmény
PT2593094T (pt) Composição aquosa contendo bromexina
SMT201500263B (it) Composizioni solide
BR112012031667A2 (pt) composição
EP2558297A4 (en) Powder overlay
DK2640893T4 (da) Sammensætninger
LT3246021T (lt) Apiksabano kompozicijos
EP2522702A4 (en) ANTI-FOG COATING COMPOSITION
IL232113A0 (en) Arginase inhibitor compounds, preparations containing them and their uses
DK2654736T3 (da) Hidtil ukendt farmaceutisk sammensætning
LT3158991T (lt) Bendamustino kompozicijos
BR112012032683A2 (pt) composição
SMT201900385T1 (it) Composto eterociclico
EP2636704A4 (en) FILM FORMING COMPOSITION
LT2865271T (lt) Pagerinta kompozicija
EP2559720A4 (en) NETWORKED COMPOSITION
BR112012032980A2 (pt) composição
EP2628769A4 (en) FILM FORMING COMPOSITION
FR2957252B1 (fr) Composition cosmetique
FR2935592B1 (fr) Poudrier
EP2635269A4 (en) COMBINATION COMPOSITION
DK2628396T3 (da) Pulverblanding
EP2623092A4 (en) COSMETIC COMPOSITION
DK2553004T3 (da) Sammensatte materialer
EP2548928A4 (en) PIGMENT COMPOSITION